Bladder cancer company Photocure ASA (OSE: PHO) announced on Monday that its partner Asieris Pharmaceuticals (SSE: 688176) presented subgroup data from its Phase III clinical trial for Cevira (APL-1702) at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting.
This trial, focused on the non-surgical treatment of cervical High-Grade Squamous Intraepithelial Lesion (HSIL), demonstrated significant pathological regression and HPV clearance rates, especially in patients aged 20 to 40.
The randomised, double-blind, placebo-controlled trial showed a 15-20% increase in pathological regression in key age groups and strong HPV clearance in younger patients. The drug-device combination offers promise as a non-invasive HSIL treatment, with further validation needed for younger and older age groups.
Cevira achieved its primary efficacy endpoint in 2023, with an NDA accepted by China's NMPA in May 2024.
ColdVentures partners with Medco Sports Medicine to combat heat stroke
Median Technologies secures funding for eyonis Lung Cancer Screening software
MicroAire Surgical Instruments acquires NEOSYAD
UCB launches 320 mg/2 mL single-injection administration option for BIMZELX (bimekizumab-bkzx) in US
Concept Medical reports first patient enrolled in MagicTouch SCB trial in peripheral artery disease
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing
Implantica publishes real-world data supporting RefluxStop efficacy
Abingdon Health subsidiary awarded GBP500,000 contract
NanoVibronix completes pilot phase of UroShield study at University of Michigan
Hologic acquires Gynesonics for USD350m
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Microtech commences human clinical trial of microsensor platform for heart failure
Humacyte Global receives approval from FDA for Symvess
Defense Diagnostics launches DEFENT ONE All-In-One Fentanyl Detection Device in US